Hydrochloric Acid

Hydrochloric Acid

SCHEMBL377646

Cl.Cl.Cl.O.O.O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 638 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113260860-B Cellular analysis of body fluids, particularly blood 上海宜晟生物科技有限公司 2025-06-13 CN claimed
CN-113227752-B Enhanced, rapid, homogeneous cell staining and assay 上海宜晟生物科技有限公司 2025-04-29 CN claimed
US-20250052753-A1 SINGLE PARTICLE ANALYSIS METHOD FOR VIRAL NUCLEIC ACID VECTOR NANOFCM ASIA PTE.LTD. (SG) 2025-02-13 US claimed
US-11906432-B2 Enhanced, rapid, homogeneous, cell staining and assay ESSENLIX CORPORATION (US) 2024-02-20 US claimed
CN-117165721-A Single particle analysis method of viral nucleic acid vector 厦门福流生物科技有限公司 2023-12-05 CN claimed
CN-115814802-A Efficient soot catalytic oxidation monolithic catalyst and preparation method thereof 中国石油化工股份有限公司 2023-03-21 CN claimed
US-11609224-B2 Devices and methods for white blood cell analyses ESSENLIX CORPORATION (US) 2023-03-21 US claimed
CN-110452683-A Compound light conversion agent of quantum dot and preparation method thereof FOSHAN ONMILLION NANO MAT CO LTD 2019-11-15 CN claimed
CN-110448700-A It is a kind of for targeting the nano drug-carrying compound and preparation method of diagnosis and treatment gastric cancer THE SIXTH AFFILIATED HOSPITAL SUN YAT SEN UNIV 2019-11-15 CN claimed
CN-110368975-A A kind of construction method of compound semiconductor photocatalytic material 盐城师范学院 2019-10-25 CN claimed
EP-0200776-B1 SOLUTION PROCESS AND SOLVENT FOR HARDLY SOLUBLE CARBONATES UHT, Umwelt- und Hygienetechnik GmbH (DE) 1989-01-18 EP claimed
EP-0262307-A2 Process for preparing hydroxymorpholines and morpholines TEXACO DEVELOPMENT CORPORATION (US) 1988-04-06 EP claimed
US-4670557-A Process for preparing hydroxymorpholines TEXACO INC. (US) 1987-06-02 US claimed
US-4469895-A PREDOMINANTLY LINEAR TEXACO INC. (US) 1984-09-04 US claimed
US-4451680-A RUTHENIUM COMPOUND, BIDENTATE OR MULTIDENTATE PHOSPHINE, PHOSPHONIUM COMPOUND TEXACO INC. (US) 1984-05-29 US claimed
US-4451679-A RUTHENIUM COMPOUNDS, PHOSPHONIUM OR QUATERNARY AMMONIUM COMPOUNDS TEXACO INC. (US) 1984-05-29 US claimed
US-4366259-A RUTHENIUM COMPOUND COBALT HALIDE OR COBALT COMPOUND AND IODINE OR IODIDE, PHOSPHONIUM OR AMMONIUM SALT TEXACO, INC. (US) 1982-12-28 US claimed
US-4362822-A FROM HYDROGEN AND CARBON MONOXIDE USING CATALYST CONTAINING A RUTHENIUM COMPOUND, HALOGEN CONTAINING TITANIUM OR ZIRCONIUM SALT DISPERSED IN QUATENARY PHOSPHONIUM OR AMMONIUM SALT TEXACO INC. (US) 1982-12-07 US claimed
US-4339545-A COMPOUND 4 CATALYSTS TEXACO INC. (US) 1982-07-13 US claimed
US-4265828-A RUTHENIUM CATALYST WITH A LOW MELTING QUATERNARY PHOSPHONIUM OR AMMONIUM SALT TEXACO DEVELOPMENT CORP. (US) 1981-05-05 US claimed